BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 18981415)

  • 1. Thymidine kinase 1 as a molecular target for boron neutron capture therapy of brain tumors.
    Barth RF; Yang W; Wu G; Swindall M; Byun Y; Narayanasamy S; Tjarks W; Tordoff K; Moeschberger ML; Eriksson S; Binns PJ; Riley KJ
    Proc Natl Acad Sci U S A; 2008 Nov; 105(45):17493-7. PubMed ID: 18981415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular influx, efflux, and anabolism of 3-carboranyl thymidine analogs: potential boron delivery agents for neutron capture therapy.
    Sjuvarsson E; Damaraju VL; Mowles D; Sawyer MB; Tiwari R; Agarwal HK; Khalil A; Hasabelnaby S; Goudah A; Nakkula RJ; Barth RF; Cass CE; Eriksson S; Tjarks W
    J Pharmacol Exp Ther; 2013 Nov; 347(2):388-97. PubMed ID: 24006340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Boron-containing nucleosides as potential delivery agents for neutron capture therapy of brain tumors.
    Barth RF; Yang W; Al-Madhoun AS; Johnsamuel J; Byun Y; Chandra S; Smith DR; Tjarks W; Eriksson S
    Cancer Res; 2004 Sep; 64(17):6287-95. PubMed ID: 15342417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of TK1 targeting carboranyl thymidine analogs as potential delivery agents for neutron capture therapy of brain tumors.
    Barth RF; Yang W; Nakkula RJ; Byun Y; Tjarks W; Wu LC; Binns PJ; Riley KJ
    Appl Radiat Isot; 2015 Dec; 106():251-5. PubMed ID: 26282567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation and biological evaluation of 10B-enriched 3-[5-{2-(2,3-dihydroxyprop-1-yl)-o-carboran-1-yl}pentan-1-yl]thymidine (N5-2OH), a new boron delivery agent for boron neutron capture therapy of brain tumors.
    Byun Y; Thirumamagal BT; Yang W; Eriksson S; Barth RF; Tjarks W
    J Med Chem; 2006 Sep; 49(18):5513-23. PubMed ID: 16942024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas.
    Barth RF; Yang W; Adams DM; Rotaru JH; Shukla S; Sekido M; Tjarks W; Fenstermaker RA; Ciesielski M; Nawrocky MM; Coderre JA
    Cancer Res; 2002 Jun; 62(11):3159-66. PubMed ID: 12036929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and evaluation of thymidine kinase 1-targeting carboranyl pyrimidine nucleoside analogs for boron neutron capture therapy of cancer.
    Agarwal HK; Khalil A; Ishita K; Yang W; Nakkula RJ; Wu LC; Ali T; Tiwari R; Byun Y; Barth RF; Tjarks W
    Eur J Med Chem; 2015 Jul; 100():197-209. PubMed ID: 26087030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of boron neutron capture therapy and external beam radiotherapy for brain tumors.
    Barth RF; Grecula JC; Yang W; Rotaru JH; Nawrocky M; Gupta N; Albertson BJ; Ferketich AK; Moeschberger ML; Coderre JA; Rofstad EK
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):267-77. PubMed ID: 14697448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rat brain tumor models to assess the efficacy of boron neutron capture therapy: a critical evaluation.
    Barth RF; Yang W; Coderre JA
    J Neurooncol; 2003; 62(1-2):61-74. PubMed ID: 12749703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of neutral and zwitterionic 3-carboranyl thymidine analogues for boron neutron capture therapy.
    Byun Y; Yan J; Al-Madhoun AS; Johnsamuel J; Yang W; Barth RF; Eriksson S; Tjarks W
    J Med Chem; 2005 Feb; 48(4):1188-98. PubMed ID: 15715485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced survival of glioma bearing rats following boron neutron capture therapy with blood-brain barrier disruption and intracarotid injection of boronophenylalanine.
    Yang W; Barth RF; Rotaru JH; Moeschberger ML; Joel DD; Nawrocky MM; Goodman JH
    J Neurooncol; 1997 May; 33(1-2):59-70. PubMed ID: 9151224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydrophilically enhanced 3-carboranyl thymidine analogues (3CTAs) for boron neutron capture therapy (BNCT) of cancer.
    Narayanasamy S; Thirumamagal BT; Johnsamuel J; Byun Y; Al-Madhoun AS; Usova E; Cosquer GY; Yan J; Bandyopadhyaya AK; Tiwari R; Eriksson S; Tjarks W
    Bioorg Med Chem; 2006 Oct; 14(20):6886-99. PubMed ID: 16831554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab.
    Wu G; Yang W; Barth RF; Kawabata S; Swindall M; Bandyopadhyaya AK; Tjarks W; Khorsandi B; Blue TE; Ferketich AK; Yang M; Christoforidis GA; Sferra TJ; Binns PJ; Riley KJ; Ciesielski MJ; Fenstermaker RA
    Clin Cancer Res; 2007 Feb; 13(4):1260-8. PubMed ID: 17317838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved survival after boron neutron capture therapy of brain tumors by Cereport-mediated blood-brain barrier modulation to enhance delivery of boronophenylalanine.
    Yang W; Barth RF; Bartus RT; Rotaru JH; Moeschberger ML; Ferketich AK; Nawrocky MM; Coderre JA; Goodman JH
    Neurosurgery; 2000 Jul; 47(1):189-97; discussion 197-8. PubMed ID: 10917362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutron capture therapy of the 9L rat gliosarcoma using the p-boronophenylalanine-fructose complex.
    Coderre JA; Button TM; Micca PL; Fisher CD; Nawrocky MM; Liu HB
    Int J Radiat Oncol Biol Phys; 1994 Oct; 30(3):643-52. PubMed ID: 7928496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Boron neutron capture therapy of brain tumors: enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood-brain barrier disruption.
    Barth RF; Yang W; Rotaru JH; Moeschberger ML; Joel DD; Nawrocky MM; Goodman JH; Soloway AH
    Cancer Res; 1997 Mar; 57(6):1129-36. PubMed ID: 9067283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4.
    Yang W; Barth RF; Wu G; Kawabata S; Sferra TJ; Bandyopadhyaya AK; Tjarks W; Ferketich AK; Moeschberger ML; Binns PJ; Riley KJ; Coderre JA; Ciesielski MJ; Fenstermaker RA; Wikstrand CJ
    Clin Cancer Res; 2006 Jun; 12(12):3792-802. PubMed ID: 16778107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents.
    Yang W; Barth RF; Wu G; Tjarks W; Binns P; Riley K
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S328-31. PubMed ID: 19467880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Boronated epidermal growth factor as a delivery agent for neutron capture therapy of EGF receptor positive gliomas.
    Yang W; Barth RF; Wu G; Bandyopadhyaya AK; Thirumamagal BT; Tjarks W; Binns PJ; Riley K; Patel H; Coderre JA; Ciesielski MJ; Fenstermaker RA
    Appl Radiat Isot; 2004 Nov; 61(5):981-5. PubMed ID: 15308179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Convection enhanced delivery of carboranylporphyrins for neutron capture therapy of brain tumors.
    Kawabata S; Yang W; Barth RF; Wu G; Huo T; Binns PJ; Riley KJ; Ongayi O; Gottumukkala V; Vicente MG
    J Neurooncol; 2011 Jun; 103(2):175-85. PubMed ID: 20848301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.